1:19
MRD testing should be more widely available
Gareth Morgan
3:01
MM treatment in the US vs. Europe: multi-drug regimens & cellular therapies
Ola Landgren
3:47
Sickle cell disease: where we are now
Maria Cappellini
1:57
Biomarkers in lymphoma
Arjan Diepstra
3:43
Predictors of outcome for follicular lymphoma
Anna Schuh
2:22
How hematologists can improve care for patients with sickle cell disease
Sonia Wolf
1:05
The CAR T-cell therapy race
Noelle Frey
1:14
An overview of 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias
Arnold Ganser
4:33
Making sense of the many treatment options for relapsed MM: cost-effectiveness
Jean-Luc Harousseau
1:02
Accelerating assessment of therapies in hematology
Charles Craddock
2:20
British Society for Haematology: driving a therapeutic revolution in hematology
Charles Craddock
1:36
ASH highlights: groundbreaking results from the TEAMM trial
Martin Kaiser
1:09
Treating GvHD: current challenges and newly approved drugs
Katie Gatwood
1:43
The importance of pharmacist intervention in the treatment of GvHD with ruxolitinib and ibrutinib
Katie Gatwood
2:29
Ruxolitinib and ibrutinib: the future for GvHD treatment?
Katie Gatwood
3:05
We know that MRD is relevant, what next?
Bijal Shah
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals